These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38718748)

  • 1. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
    Signoriello E; Signori A; Lus G; Romano G; Marfia GA; Landi D; Napoli F; D' Amico E; Zanghí A; Di Filippo PS; Caliendo D; Carotenuto A; Spiezia AL; Fantozzi R; Centonze D; Lucchini M; Mirabella M; Cocco E; Frau J; Maniscalco GT; Di Battista ME; Foschi M; Surcinelli A; Bonavita S; Abbadessa G; Pasquali L; Di Gregorio M; Ferrò MT; Sormani MP; Schiavetti I;
    Mult Scler Relat Disord; 2024 Jul; 87():105594. PubMed ID: 38718748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
    Lorefice L; Mellino P; Frau J; Coghe G; Fenu G; Cocco E
    Neurol Sci; 2024 Aug; 45(8):3951-3959. PubMed ID: 38472551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    Zanghì A; Borriello G; Bonavita S; Fantozzi R; Signoriello E; Barone S; Abbadessa G; Cellerino M; Ziccone V; Miele G; Lus G; Valentino P; Bucello S; Inglese M; Centonze D; Avolio C; D'Amico E
    J Neurol; 2024 Jul; 271(7):4495-4502. PubMed ID: 38704488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of monoclonal antibodies in the treatment of patients with high-active multiple sclerosis in real clinical practice].
    Kotov SV; Yakushina TI; Novikova ES; Lizhdvoy VY; Belova YA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7. Vyp. 2):77-83. PubMed ID: 37560838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
    Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
    Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
    Iaffaldano P; Lucisano G; Guerra T; Paolicelli D; Portaccio E; Inglese M; Foschi M; Patti F; Granella F; Romano S; Cavalla P; De Luca G; Gallo P; Bellantonio P; Gallo A; Montepietra S; Di Sapio A; Vianello M; Quatrale R; Spitaleri D; Clerici R; Torri Clerici V; Cocco E; Brescia Morra V; Marfia GA; Boccia VD; Filippi M; Amato MP; Trojano M;
    Ann Clin Transl Neurol; 2024 Aug; 11(8):2008-2015. PubMed ID: 38970214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers.
    Diem L; Ovchinnikov A; Friedli C; Hammer H; Kamber N; Chan A; Salmen A; Findling O; Hoepner R
    Mult Scler Relat Disord; 2024 Jun; 86():105570. PubMed ID: 38604001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
    Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
    JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
    Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
    Graille-Avy L; Boutiere C; Rigollet C; Perriguey M; Rico A; Demortiere S; Durozard P; Hilezian F; Vely F; Bertault-Peres P; Pelletier J; Maarouf A; Audoin B
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200231. PubMed ID: 38626360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.